What is Olio Labs?
Olio Labs operates at the intersection of artificial intelligence and advanced pharmacology, specializing in the development of combination therapeutics. Unlike traditional drug discovery models that often isolate single protein targets, Olio Labs utilizes sophisticated AI algorithms to map and address the complex, multi-protein interactions inherent in human disease. This holistic methodology is designed to enhance treatment efficacy while simultaneously reducing the incidence of adverse side effects.
The company serves a critical niche within the healthcare ecosystem, providing innovative solutions for researchers and providers tasked with treating some of the world's most challenging medical conditions. By focusing on the systemic nature of disease, Olio Labs is establishing a new standard for therapeutic precision, positioning itself as a high-growth entity within the biotechnology sector.
How much funding has Olio Labs raised?
Olio Labs has raised a total of $4.5M across 1 funding round:
Other Financing Round
$4.5M
Other Financing Round (2025): $4.5M with participation from SciFounders, Pioneer Fund, Scrum Ventures, Boom Capital, Zaka Group, and Overwater Ventures
Key Investors in Olio Labs
SciFounders
An investment firm dedicated to supporting highly technical startups from the idea stage through Series A, providing both capital and hands-on mentorship.
Pioneer Fund
A founder-led investment vehicle backed by over 200 Y Combinator alumni, focused on providing strategic guidance and rapid decision-making for high-potential startups.
Scrum Ventures
An early-stage venture firm based in San Francisco that leverages extensive networks in the U.S. and Japan to accelerate global growth for its portfolio companies.
What's next for Olio Labs?
With this major enterprise-level funding secured, Olio Labs is poised to shift its strategic focus toward the commercialization of its lead therapeutic candidates. The company is expected to prioritize the expansion of its computational biology team and the strengthening of its R&D capabilities to facilitate the transition from laboratory discovery to clinical trials.
Furthermore, the strategic nature of this investment suggests a roadmap that includes potential partnerships with global healthcare providers and pharmaceutical entities. By maintaining its focus on high-impact, protein-interaction-based treatments, Olio Labs is well-positioned to navigate the complexities of the regulatory landscape while scaling its operations to meet the growing demand for more effective, AI-informed medical interventions.
